Skip to main content
. 2023 Oct 25;31:61. doi: 10.1186/s13049-023-01134-5

Fig. 2.

Fig. 2

A APD30 (ms) for the lowest concentrations of levosimendan (0.1 µM, n = 9), milrinone (1 µM, n = 9) and isoprenaline (0.01 µM, n = 9) during hypothermia and rewarming. B APD30 (ms) for the different levosimendan concentrations (0.1 µM, 1 µM and 10 µM). C APD30 (ms) for the intermediate concentrations of levosimendan (1 µM, n = 9), milrinone (10 µM, n = 9) and isoprenaline (0.1 µM, n = 9) during hypothermia and rewarming. D APD30 (ms) for the different milrinone concentrations (1 µM, 10 µM and 100 µM). E APD30 (ms) for the highest concentrations of levosimendan (10 µM, n = 9), milrinone (100 µM, n = 9) and isoprenaline (1 µM, n = 9) during hypothermia and rewarming. F APD30 (ms) for the different isoprenaline concentrations (0.01 µM, 0.1 µM and 1 µM). A, C, E *Significant differences between levosimendan and DMSO 0.1% (n = 15), #significant difference between milrinone and DMSO 0.1% (n = 15), $significant difference between isoprenaline and DMSO 0.1% (n = 15). B, D, F *Significant difference between lowest and intermediate concentration, #significant difference between lowest and highest concentration, $significant difference between intermediate and highest concentration